<html lang="en" class="pb-page js" data-request-id="9523b0aab351010f-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="9523b0aab351010f-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script nonce="9523b0aab351010f-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.27204144520567464"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-402" async="async" crossorigin="" importance="high" nonce="9523b0aab351010f-SJC"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Childhood Diseases|Tuberculosis|Diagnostics|Global Health">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease|Pediatrics"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2104535","title":"Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children","category":"Research","type":"Original Article","topics":"Childhood Diseases|Tuberculosis|Diagnostics|Global Health","specialties":"Infectious Disease|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-03-10T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Childhood Diseases|Tuberculosis|Diagnostics|Global Health\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease|Pediatrics\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2104535","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Shorter Treatment for Nonsevere TB in Children","doi":"10.1056/NEJMdo006409","issueDate":"2022-03-10T00:00Z","age":"6Months-1990","isFree":"n","topics":"Childhood Diseases|Tuberculosis|Diagnostics|Global Health","viewType":"Full","specialties":"Infectious Disease|Pediatrics"},{"type":"Research Summary","title":"Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children","doi":"10.1056/NEJMdo006410","issueDate":"2022-03-10T00:00Z","age":"6Months-1990","isFree":"n","topics":"Childhood Diseases|Tuberculosis|Diagnostics|Global Health","viewType":"Full","specialties":"Infectious Disease|Pediatrics"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="9523b0aab351010f-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);


</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children"><meta name="dc.Creator" content="Anna Turkova"><meta name="dc.Creator" content="Genevieve H. Wills"><meta name="dc.Creator" content="Eric Wobudeya"><meta name="dc.Creator" content="Chishala Chabala"><meta name="dc.Creator" content="Megan Palmer"><meta name="dc.Creator" content="Aarti Kinikar"><meta name="dc.Creator" content="Syed Hissar"><meta name="dc.Creator" content="Louise Choo"><meta name="dc.Creator" content="Philippa Musoke"><meta name="dc.Creator" content="Veronica Mulenga"><meta name="dc.Creator" content="Vidya Mave"><meta name="dc.Creator" content="Bency Joseph"><meta name="dc.Creator" content="Kristen LeBeau"><meta name="dc.Creator" content="Margaret J. Thomason"><meta name="dc.Creator" content="Robert B. Mboizi"><meta name="dc.Creator" content="Monica Kapasa"><meta name="dc.Creator" content="Marieke M. van der Zalm"><meta name="dc.Creator" content="Priyanka Raichur"><meta name="dc.Creator" content="Perumal K. Bhavani"><meta name="dc.Creator" content="Helen McIlleron"><meta name="dc.Creator" content="Anne-Marie Demers"><meta name="dc.Creator" content="Rob Aarnoutse"><meta name="dc.Creator" content="James Love-Koh"><meta name="dc.Creator" content="James A. Seddon"><meta name="dc.Creator" content="Steven B. Welch"><meta name="dc.Creator" content="Stephen M. Graham"><meta name="dc.Creator" content="Anneke C. Hesseling"><meta name="dc.Creator" content="Diana M. Gibb"><meta name="dc.Creator" content="Angela M. Crook"><meta name="dc.Description" content="Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen.We conducted an open-label, treatment-shortening, non..."><meta name="Description" content="Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen.We conducted an open-label, treatment-shortening, non..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-03-10"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2104535"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202203103861005"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2200966"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2104535">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2104535">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2104535">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children | NEJM">
        <meta property="og:title" content="Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2104535">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/43eede6a-d10d-4747-a447-8ac89094fe5f/nejmoa2104535_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/43eede6a-d10d-4747-a447-8ac89094fe5f/nejmoa2104535_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Two thirds of children with tuberculosis have nonsevere disease, which may be treatable
with a shorter regimen than the current 6-month regimen. We conducted an open-label,
treatment-shortening, no...">
        <meta name="twitter:description" content="Two thirds of children with tuberculosis have nonsevere disease, which may be treatable
with a shorter regimen than the current 6-month regimen. We conducted an open-label,
treatment-shortening, no...">
    


    
    
        <meta property="og:image:width" content="2622">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2104535">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104535">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2104535;issue:issue:doi\:10.1056/nejm_2022.386.issue-10;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><style type="text/css" id="bc_async_1750343067752">div[id='bc_home_trend'] {opacity:0.0;filter:alpha(opacity=0);}
</style><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104535" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104535" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/research-summary" class="ng-simple-menu_list-link">Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2104535" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2104535" class="inputDoi"><input type="hidden" value="A. Turkova and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:911-922" class="inputCitation"><input type="hidden" value="03-09-2022" class="inputEPubDate"><input type="hidden" value="March 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="9523b0aab351010f-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Turkova</span>, <span property="honorificSuffix">M.R.C.P.C.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Genevieve H.</span> <span property="familyName">Wills</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eric</span> <span property="familyName">Wobudeya</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chishala</span> <span property="familyName">Chabala</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Megan</span> <span property="familyName">Palmer</span>, <span property="honorificSuffix">M.B., Ch.B., M.Med.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aarti</span> <span property="familyName">Kinikar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Syed</span> <span property="familyName">Hissar</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+22</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Louise</span> <span property="familyName">Choo</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philippa</span> <span property="familyName">Musoke</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Veronica</span> <span property="familyName">Mulenga</span>, <span property="honorificSuffix">M.Med., M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vidya</span> <span property="familyName">Mave</span>, <span property="honorificSuffix">M.D., M.P.H.&amp;T.M.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bency</span> <span property="familyName">Joseph</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kristen</span> <span property="familyName">LeBeau</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Margaret J.</span> <span property="familyName">Thomason</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert B.</span> <span property="familyName">Mboizi</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Monica</span> <span property="familyName">Kapasa</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marieke M.</span> <span property="familyName">van der Zalm</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Priyanka</span> <span property="familyName">Raichur</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Perumal K.</span> <span property="familyName">Bhavani</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Helen</span> <span property="familyName">McIlleron</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anne-Marie</span> <span property="familyName">Demers</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rob</span> <span property="familyName">Aarnoutse</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James</span> <span property="familyName">Love-Koh</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James A.</span> <span property="familyName">Seddon</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Steven B.</span> <span property="familyName">Welch</span>, <span property="honorificSuffix">F.R.C.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen M.</span> <span property="familyName">Graham</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anneke C.</span> <span property="familyName">Hesseling</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Diana M.</span> <span property="familyName">Gibb</span>, <span property="honorificSuffix">M.B., Ch.B., M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Angela M.</span> <span property="familyName">Crook</span>, <span property="honorificSuffix">Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the SHINE Trial Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-22</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 9, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">911</span>-<span property="pageEnd">922</span></div><div class="doi">DOI: 10.1056/NEJMoa2104535</div><div class="core-enumeration"><a href="/toc/nejm/386/10"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">10</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAnna%2BTurkova%252C%2BGenevieve%2BH.%2BWills%252C%2BEric%2BWobudeya%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2104535%26title%3DShorter%2BTreatment%2Bfor%2BNonsevere%2BTuberculosis%2Bin%2BAfrican%2Band%2BIndian%2BChildren%26publicationDate%3D03%252F10%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2104535" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAnna%2BTurkova%252C%2BGenevieve%2BH.%2BWills%252C%2BEric%2BWobudeya%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2104535%26title%3DShorter%2BTreatment%2Bfor%2BNonsevere%2BTuberculosis%2Bin%2BAfrican%2Band%2BIndian%2BChildren%26publicationDate%3D03%252F10%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/944fb0ca-0a42-48e6-99a1-1b094a5b76ca/nejmoa2104535.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2104535.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2104535" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2104535" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104535.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted an open-label, treatment-shortening, noninferiority trial involving children with nonsevere, symptomatic, presumably drug-susceptible, smear-negative tuberculosis in Uganda, Zambia, South Africa, and India. Children younger than 16 years of age were randomly assigned to 4 months (16 weeks) or 6 months (24 weeks) of standard first-line antituberculosis treatment with pediatric fixed-dose combinations as recommended by the World Health Organization. The primary efficacy outcome was unfavorable status (composite of treatment failure [extension, change, or restart of treatment or tuberculosis recurrence], loss to follow-up during treatment, or death) by 72 weeks, with the exclusion of participants who did not complete 4 months of treatment (modified intention-to-treat population). A noninferiority margin of 6 percentage points was used. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment.<div data-style-type="float-right"><div class="core-digital-object nejm-research-summary">
    <div class="ng-do-media" data-location="inlineArticlePreview">
        <div class="ng-do-media_item">
            <div class="ng-do-media_item-left">
                <a href="/do/10.1056/NEJMdo006410/full/" class="ng-do-media_item-img-link">
                    <img src="/cms/asset/27e2ca21-6f50-4e93-82c3-8f04d1276da5/nejmdo006410_thumb.jpg" class="ng-do-media_item-img">
                </a>
            </div>
            <div class="ng-do-media_item-right">
                <div class="ng-do-media_item-type">
                    <a href="/browse/nejm-media-type/research-summary" class="ng-do-media_item-type-link">Research Summary</a>
                </div>
                <h6 class="ng-do-media_item-title">
                    <a href="/do/10.1056/NEJMdo006410/full/" class="ng-do-media_item-title-link">Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children</a>
                </h6>
            </div>
        </div>
    </div>
    <div class="ng-page_separator mt-32"></div>
</div></div></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">From July 2016 through July 2018, a total of 1204 children underwent randomization (602 in each group). The median age of the participants was 3.5 years (range, 2 months to 15 years), 52% were male, 11% had human immunodeficiency virus infection, and 14% had bacteriologically confirmed tuberculosis. Retention by 72 weeks was 95%, and adherence to the assigned treatment was 94%. A total of 16 participants (3%) in the 4-month group had a primary-outcome event, as compared with 18 (3%) in the 6-month group (adjusted difference, −0.4 percentage points; 95% confidence interval, −2.2 to 1.5). The noninferiority of 4 months of treatment was consistent across the intention-to-treat, per-protocol, and key secondary analyses, including when the analysis was restricted to the 958 participants (80%) independently adjudicated to have tuberculosis at baseline. A total of 95 participants (8%) had an adverse event of grade 3 or higher, including 15 adverse drug reactions (11 hepatic events, all but 2 of which occurred within the first 8 weeks, when the treatments were the same in the two groups).</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis. (Funded by the U.K. Medical Research Council and others; SHINE ISRCTN number, <a href="https://www.isrctn.com/ISRCTN63579542" target="_blank">ISRCTN63579542</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006409/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/f85cdad0-e08a-478f-bff1-143a15a4cd20/media/NEJMdo006409_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006409/full/" class="ng-do-media_item-title-link">Shorter Treatment for Nonsevere TB in Children</a>
            </h6>
            <div class="ng-do-media_item-duration">1m 45s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><a id="exam-tint-one-c"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-c">More than 1 million children become ill with tuberculosis annually, and almost 20% of them die,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> but children have historically been excluded from clinical efficacy trials of antituberculosis treatment. This situation is due in part to low rates of bacteriologic confirmation of disease among children, given high rates of paucibacillary disease and difficulties in obtaining respiratory specimens. Treatment recommendations for children are therefore extrapolated from trials involving adults for which the criteria for treatment entry have often included smear-positive respiratory disease.</span></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-d">In contrast to adults, most children have nonsevere, smear-negative tuberculosis.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4" href-manipulated="true">3,4</a></sup> Although spontaneous resolution has been described,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> it is generally agreed that treatment is appropriate in children with mild forms of tuberculosis because of the risk of disease progression and dissemination, particularly among the youngest children or those with concurrent human immunodeficiency virus (HIV) infection.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> It is likely that nonsevere forms of tuberculosis could be treated with shorter durations of therapy, but data are limited regarding the shortening of treatment for drug-susceptible tuberculosis in children. Current international guidelines recommend 6 months of antituberculosis treatment in children, which is the same duration as in adults.</span></div><div role="paragraph">Early pharmacokinetic studies of first-line antituberculosis treatment showed lower drug exposures in young children than in adults and led to recommendations of increased drug doses from the World Health Organization (WHO) in 2010.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> New dispersible-formulation tablets with a fixed-dose combination were developed to enable the use of revised doses and became available in 2015.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10" id="body-ref-r10-1" href-manipulated="true">9,10</a></sup></div><div role="paragraph">In the SHINE trial, we investigated whether 4 months of antituberculosis treatment would be as good as 6 months of treatment in children with nonsevere, smear-negative, presumably drug-susceptible tuberculosis, using the new fixed-dose combination formulations. In addition, we evaluated the cost-effectiveness of the 4-month treatment approach.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">We conducted an international, open-label, parallel-group, randomized, controlled, noninferiority trial comparing 4 months (16 weeks) of antituberculosis treatment with the standard 6 months (24 weeks) of treatment using WHO-recommended pediatric doses.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> All the relevant national and local ethics committees and the University College London research ethics committee approved the trial <a href="#ap1">protocol</a>, which is available with the full text of this article at NEJM.org. Caregivers provided written informed consent, and children gave assent as appropriate. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Participants</h3><div role="paragraph">Children younger than 16 years of age who had symptomatic nonsevere tuberculosis that was smear-negative on a respiratory sample and who were due to start first-line antituberculosis treatment were eligible for enrollment. Nonsevere tuberculosis included respiratory tuberculosis confined to one lobe (opacification of &lt;1 lobe) with no cavities, no signs of miliary tuberculosis, no complex pleural effusion, and no clinically significant airway obstruction or peripheral lymph-node tuberculosis (see the protocol).<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup></div></section><section id="sec-1-3"><h3>Trial Procedures</h3><div role="paragraph">Children were seen at screening, at enrollment (randomization), and at weeks 2, 4, 8, 12, 16, 20, 24, 28, 36, 48, 60, and 72. Screening procedures included history taking to identify contacts with persons with tuberculosis and an evaluation of symptoms associated with tuberculosis; performance of a Mantoux tuberculin skin test or interferon γ–release assay, where available; radiography of the chest; and obtaining at least two respiratory samples (gastric aspirate, expectorated sputum, or induced sputum) for smear microscopy, Xpert MTB/RIF assay (Xpert, Cepheid), mycobacterial culture (Löwenstein–Jensen solid-culture medium or a mycobacteria growth indicator tube with liquid culture system), and drug-susceptibility testing. In children with peripheral lymph-node tuberculosis, a fine-needle aspirate was obtained. A baseline radiograph of the chest was assessed by site clinicians for severe respiratory tuberculosis.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup> Blood samples for biochemical and hematologic testing (in all children) and for HIV type 1 viral load and CD4 count (in children with HIV infection) were obtained at screening and at scheduled follow-up visits. Children with confirmed drug resistance or with known exposure to an adult with any drug-resistant tuberculosis were excluded from the trial.</div><div role="paragraph">A symptom checklist was completed and a clinical examination was performed at each visit to detect tuberculosis-associated symptoms and adverse events. Repeat respiratory samples were obtained if previous respiratory specimens were positive on microbiologic testing, if such assessment was clinically indicated to assess recurrence or treatment failure, or if a new contact with drug-resistant tuberculosis was identified.</div><div role="paragraph">Radiographs of the chest were retrospectively reviewed centrally by two independent experts. Radiographs with discordant interpretations at the primary reading were reviewed by a third expert, and the majority opinion was used. The radiographic image review was conducted in a blinded manner with the use of a standardized approach (see the protocol). Tuberculosis status at enrollment (confirmed, unconfirmed, or unlikely) was adjudicated by an independent clinical expert committee on the basis of all available clinical, radiologic, and laboratory data.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> An end-point review committee, whose members were unaware of the treatment assignments, reviewed clinical events suggestive of treatment failure or tuberculosis recurrence and all deaths. Clinical and laboratory adverse events of grade 3 or higher were defined with the use of the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> Additional notable events to be reported included suspected bacterial infection leading to hospitalization, ocular toxic effects, and pregnancy.</div><div role="paragraph">Adherence was assessed by means of pill counts at each visit during treatment and by the administration of adherence questionnaires at the end of the intensive phase (first 8 weeks of treatment) and at the end of treatment. Treatment extensions due to excessive missed doses were reconciled against pill-count data.</div></section><section id="sec-1-4"><h3>Randomization and Treatment</h3><div role="paragraph">Eligible children were randomly assigned in a 1:1 ratio to receive 4 months or 6 months of antituberculosis treatment. Randomization was conducted with the use of minimization (with a random element) according to trial center, age (&lt;3 years or ≥3 years), HIV status, and ethambutol use.</div><div role="paragraph">All the participants initially received 8 weeks of standard therapy with isoniazid, rifampin, and pyrazinamide (fixed-dose combination formulation), with or without ethambutol according to local guidelines (intensive phase). This treatment was followed by standard therapy with isoniazid and rifampin (continuation phase) in a fixed-dose combination for either 8 weeks in the 4-month group (intervention) or 16 weeks in the 6-month group (control). All antituberculosis treatment was administered 7 days per week, on the basis of WHO weight bands for tuberculosis treatment, with the use of child-friendly formulations<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-3" href-manipulated="true" aria-label="Reference 10">10</a></sup> that have been found to be acceptable by trial participants and caregivers.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> Directly observed treatment by health care workers was not used.</div></section><section id="sec-1-5"><h3>Primary and Secondary Outcomes</h3><div role="paragraph">The primary efficacy outcome was unfavorable status by 72 weeks. Unfavorable status was defined as a composite of tuberculosis events (treatment failure, including treatment extension beyond the replacement of missed doses, antituberculosis-treatment drug change or restart due to suspected treatment failure, and tuberculosis recurrence as adjudicated by the end-point review committee), loss to follow-up during treatment, or death from any cause. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment. The key secondary efficacy outcome was unfavorable status at 72 weeks in participants who were adjudicated by the end-point review committee as having tuberculosis at baseline. Other secondary outcomes were death; adverse drug events that were considered by the site investigators to be possibly, probably, or definitely related to a trial drug (adverse drug reactions); bacterial infection leading to hospitalization; adherence to the treatment regimen; and acceptability of treatment as determined by the caregiver (or by the child, when appropriate).</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">We determined the statistical power of the trial on the basis of a key subgroup analysis involving children who were found on independent adjudication to have tuberculosis at enrollment (80% of the intention-to-treat population). Assuming a 10% loss to follow-up (after treatment), an unfavorable status by 72 weeks (primary efficacy outcome) in 8% of the participants in the control group,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18" href-manipulated="true">17,18</a></sup> and a noninferiority margin of 6 percentage points, we calculated that the enrollment of 1200 children would provide the trial with 90% power to detect noninferiority at a two-sided significance level of 5% (see the statistical analysis plan, available with the protocol).</div><div role="paragraph">The primary modified intention-to-treat population included all the children who had undergone randomization except those who did not complete 4 months of treatment (when the treatment in the two groups was the same) or had a late exclusion (on the basis of data collected before randomization) and those who were clinically well after the completion of treatment but were subsequently lost to follow-up. For the per-protocol population, an additional exclusion criterion was the receipt of trial medications at less than 80% of the daily doses within 120% of the assigned treatment duration (prespecified in the statistical analysis plan).</div><div role="paragraph">The primary efficacy analysis was based on the absolute difference between the 4-month and 6-month strategies in the percentages of participants with an unfavorable status in the modified intention-to-treat population, with adjustment for minimization factors with Cochran–Mantel–Haenszel weights. Time-to-event analyses of unfavorable status and death were conducted with the use of log-rank tests and Cox proportional-hazards models. Analyses were performed with the use of Stata software, version 15.1 or later (StataCorp), and SAS software, version 10.1 (SAS Institute). An independent data monitoring committee reviewed data according to treatment group four times during the trial.</div><div role="paragraph">We performed economic analyses to estimate costs and health outcomes in terms of life-years and quality-adjusted life-years during the 72-week trial. In these analyses, we used data on resources that had been used in the trial and the unit costs obtained from published sources for each country. Costs were estimated from a health-sector perspective to capture a range of health care resource use, including hospitalization, medication, and testing costs. We estimated quality-adjusted life-years by combining health-related quality-of-life scores, which were estimated with the use of the European Quality of Life–5 Dimensions questionnaire, and survival. Costs and outcomes were discounted at 3% per annum, in line with international recommendations<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> (see Section S7 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">Of the 1461 children who were screened, 1204 underwent randomization between July 2016 and July 2018. A total of 376 participants were in Uganda, 364 in Zambia, 315 in South Africa, and 149 in India. The principal reasons for ineligibility were smear-positive respiratory samples and the presence of severe tuberculosis on chest radiography (<a href="#f1">Figure 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f1.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/43eede6a-d10d-4747-a447-8ac89094fe5f/assets/images/large/nejmoa2104535_f1.jpg" height="3438" width="2622" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization and Treatment of the Patients.</div><div class="notes"><div role="doc-footnote">All the eligible participants with tuberculosis (TB) initially received 8 weeks of standard therapy with isoniazid, rifampin, and pyrazinamide (fixed-dose combination formulation), with or without ethambutol according to local guidelines (intensive phase). This treatment was followed by standard therapy with isoniazid and rifampin (continuation phase) in a fixed-dose combination for either 8 weeks in the 4-month group (intervention) or 16 weeks in the 6-month group (control). MDR-TB denotes multidrug-resistant TB.</div></div></figcaption></figure></div><div role="paragraph">A total of 59 children (30 in the 4-month group and 29 in the 6-month group) were excluded from the modified intention-to-treat analysis. A total of 36 participants (18 in the 4-month group and 18 in the 6-month group) did not complete 4 months of treatment (i.e., had a protocol-defined unfavorable status before month 4), and 14 participants (8 in the 4-month group and 6 in the 6-month group) were lost to follow-up after successfully completing treatment. The most frequent reason for further exclusion from the per-protocol analysis was nonadherence to the assigned treatment strategy (in 9 participants in the 4-month group and 15 in the 6-month group) (<a href="#f1">Figure 1</a>).</div><div role="paragraph">The demographic and clinical characteristics of the participating children were similar in the two groups (<a href="#t1">Table 1</a>). The median age of the participants was 3.5 years (range, 2 months to 15 years). A total of 52% of the participants were male, 88% were African, and 12% were Indian; 11% of the participants had HIV infection. A total of 67% of the participants had respiratory tuberculosis, 3% had peripheral lymph-node tuberculosis, and 29% had mixed tuberculosis (respiratory and peripheral lymph-node disease). A total of 14% of the participants had tuberculosis that was bacteriologically confirmed as positive for <i>Mycobacterium tuberculosis</i> on culture or Xpert testing. Xpert semiquantitative results showed that all positive Xpert values were low or very low (Table S1 in the <a href="#ap2">Supplementary Appendix</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t1.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/08202639-4da3-4ffc-ba03-61f943dac5fc/assets/images/large/nejmoa2104535_t1.jpg" height="2188" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">4-Month Treatment<br>(N=602)</th><th class="txxx-borders">6-Month Treatment<br>(N=602)</th><th class="txxr-borders">Total<br>(N=1204)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (interquartile range) — yr</td><td class="xxxx-borders">3.4 (1.5 to 6.9)</td><td class="xxxx-borders">3.5 (1.5 to 7.1)</td><td class="xxxr-borders">3.5 (1.5 to 7.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">2 mo to 15 yr</td><td class="xxxx-borders shading">2 mo to 15 yr</td><td class="xxxr-borders shading">2 mo to 15 yr</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">297 (49)</td><td class="xxxx-borders">286 (48)</td><td class="xxxr-borders">583 (48)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Site country — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Uganda</td><td class="xxxx-borders">188 (31)</td><td class="xxxx-borders">188 (31)</td><td class="xxxr-borders">376 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Zambia</td><td class="xxxx-borders shading">183 (30)</td><td class="xxxx-borders shading">181 (30)</td><td class="xxxr-borders shading">364 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">South Africa</td><td class="xxxx-borders">156 (26)</td><td class="xxxx-borders">159 (26)</td><td class="xxxr-borders">315 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">India</td><td class="xxxx-borders shading">75 (12)</td><td class="xxxx-borders shading">74 (12)</td><td class="xxxr-borders shading">149 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">HIV-positive status — no. (%)</td><td class="xxxx-borders">65 (11)</td><td class="xxxx-borders">62 (10)</td><td class="xxxr-borders">127 (11)</td></tr><tr data-type="row"><td class="xxlx-borders shading">WHO weight band — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3–3.9 kg</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxr-borders">3 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4–7.9 kg</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxx-borders shading">92 (15)</td><td class="xxxr-borders shading">178 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">8–11.9 kg</td><td class="xxxx-borders">162 (27)</td><td class="xxxx-borders">152 (25)</td><td class="xxxr-borders">314 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">12–15.9 kg</td><td class="xxxx-borders shading">126 (21)</td><td class="xxxx-borders shading">116 (19)</td><td class="xxxr-borders shading">242 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">16–24.9 kg</td><td class="xxxx-borders">142 (24)</td><td class="xxxx-borders">153 (25)</td><td class="xxxr-borders">295 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥25 kg</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxr-borders shading">172 (14)</td></tr><tr data-type="row"><td class="xxlx-borders">Clinical presentation — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Respiratory tuberculosis</td><td class="xxxx-borders shading">398 (66)</td><td class="xxxx-borders shading">406 (67)</td><td class="xxxr-borders shading">804 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mixed respiratory and peripheral lymph-node tuberculosis</td><td class="xxxx-borders">182 (30)</td><td class="xxxx-borders">171 (28)</td><td class="xxxr-borders">353 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral lymph-node tuberculosis</td><td class="xxxx-borders shading">19 (3)</td><td class="xxxx-borders shading">21 (3)</td><td class="xxxr-borders shading">40 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">7 (1)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><i>M. tuberculosis</i> culture and Xpert MTB/RIF testing results — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">All positive results</td><td class="xxxx-borders">85 (14)</td><td class="xxxx-borders">80 (13)</td><td class="xxxr-borders">165 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Tuberculosis culture–positive only</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">80 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Xpert MTB/RIF–positive only</td><td class="xxxx-borders">14 (2)</td><td class="xxxx-borders">5 (1)</td><td class="xxxr-borders">19 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Tuberculosis culture–positive and Xpert MTB/RIF–positive</td><td class="xbxx-borders shading">31 (5)</td><td class="xbxx-borders shading">35 (6)</td><td class="xbxr-borders shading">66 (5)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">HIV denotes human immunodeficiency virus, and WHO World Health Organization.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">These participants did not have a cough for more than 2 weeks or one or more peripheral lymph nodes suggestive of tuberculosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Microbiologic confirmation was from respiratory samples (gastric aspirate or washing or induced or expectorated sputum) and fine-needle aspiration of enlarged lymph nodes and was defined as positive for <i>Mycobacterium tuberculosis</i> on culture or the Xpert MTB/RIF assay. Cultures were assessed with Löwenstein–Jensen solid-culture medium or a mycobacteria growth indicator tube with liquid culture system.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Retention and Treatment Adherence</h3><div role="paragraph">Retention, as assessed on the basis of attendance at the final trial visit at week 72, was 95% among those expected (excluding formal withdrawals [8 participants] and deaths [31]). Retention was similar in the two groups (Table S2).</div><div role="paragraph">Adherence to the assigned treatment duration was similar in the two groups, with 94% of the children taking at least 80% of daily doses within 120% of the assigned days (Fig. S1). Radiographs of the chest with discordant interpretations at the primary (baseline) reading were reviewed by a third expert for 435 of 1174 participants (37%). Chest radiographs that had been obtained at baseline were missing for 30 participants.</div></section><section id="sec-2-3"><h3>Primary Outcome</h3><div role="paragraph">In the modified intention-to-treat analysis, 21 events occurring before month 4 were excluded (11 deaths, 5 events of tuberculosis progression, and 5 treatment extensions or drug changes) (<a href="#f1">Figure 1</a>). <a id="exam-tint-two-c"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-c">In the primary modified intention-to-treat analysis, an unfavorable status was observed in 16 participants (3%) in the 4-month group and in 18 participants (3%) in the 6-month group (unadjusted difference, −0.3 percentage points; 95% confidence interval [CI], −2.3 to 1.6; adjusted difference, −0.4 percentage points; 95% CI, −2.2 to 1.5) (<a href="#f2">Figure 2</a> and <a href="#t2">Table 2</a>).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f2.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/ff43ac35-9290-4e67-85f4-534e13431073/assets/images/large/nejmoa2104535_f2.jpg" height="1115" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Unadjusted Analysis of the Primary Efficacy and Key Secondary Outcomes in the Trial Populations.</div><div class="notes"><div role="doc-footnote">The primary efficacy outcome was unfavorable status by 72 weeks, which was defined as a composite of treatment failure (treatment extension, change, or restart or tuberculosis recurrence), loss to follow-up during treatment, or death, with the exclusion of all the participants who had undergone randomization but did not complete 4 months of treatment (modified intention-to-treat population). The per-protocol population included all the participants in the modified intention-to-treat population except those who had not adhered to the trial regimen. The intention-to-treat population included all the participants who had undergone randomization. Differences have been carried to one decimal place because of the small values. The prespecified margin for noninferiority in the primary efficacy analysis was 6 percentage points (dashed line). The key secondary analysis was unfavorable status at 72 weeks as assessed among the 958 participants who had been independently adjudicated as having tuberculosis at baseline.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t2.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/7d59b833-5a60-4d19-b311-360df828c116/assets/images/large/nejmoa2104535_t2.jpg" height="1506" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">4-Month Treatment<br>(N=572)</th><th class="txxx-borders">6-Month Treatment<br>(N=573)</th><th class="txxr-borders" colspan="2"><span>Difference (95% CI)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">Adjusted Analysis<a href="#t2fn2" role="doc-noteref">†</a></th><th class="xxxr-borders">Unadjusted Analysis</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>percentage points</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Unfavorable status — no. (%)</td><td class="xxxx-borders shading">16 (3)</td><td class="xxxx-borders shading">18 (3)</td><td class="xxxx-borders shading">−0.4<br>(−2.2 to 1.5)</td><td class="xxxr-borders shading">−0.3<br>(−2.3 to 1.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death from any cause after 4 mo</td><td class="xxxx-borders">7 (1)</td><td class="xxxx-borders">12 (2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Loss to follow-up after 4 mo but during treatment period</td><td class="xxxx-borders shading">0<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Treatment failure</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Tuberculosis recurrence</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxx-borders shading">4 (1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Extension of treatment</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Restart of treatment<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Favorable status — no. (%)</td><td class="xbxx-borders">556 (97)</td><td class="xbxx-borders">555 (97)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Primary Efficacy Analysis (Modified Intention-to-Treat Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The primary efficacy outcome was unfavorable status by 72 weeks. Unfavorable status was defined as a tuberculosis event (treatment failure, including treatment extension beyond the replacement of missed doses, drug changes or restarts in antituberculosis treatment due to suspected treatment failure, and tuberculosis recurrence as adjudicated by the end-point review committee, whose members were unaware of the treatment assignments), loss to follow-up during treatment, or death from any cause. Favorable status was defined as the completion of treatment and a status of being clinically well, without having had retreatment or another unfavorable outcome. The primary modified intention-to-treat population included all the participants who had undergone randomization except those who did not complete 4 months of treatment or who had a late exclusion (on the basis of data collated before randomization) and those who were clinically well after the completion of treatment but were subsequently lost to follow-up.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The analysis was adjusted with Cochran–Mantel–Haenszel weighting for trial center, participant age (&lt;3 years or ≥3 years), HIV status, and ethambutol use.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">None of the participants extended their treatment beyond 4 months and were subsequently lost to follow-up.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Two participants stopped treatment and had their treatment course restarted from the beginning during the first 8 weeks.</div></div></div></figcaption></figure></div><div role="paragraph">Results in the intention-to-treat and per-protocol populations were similar to those of the primary analysis (<a href="#f2">Figure 2</a> and Table S9). In time-to-event analyses, there were no significant between-group differences in the risks of an unfavorable status (hazard ratio, 0.88; 95% CI, 0.45 to 1.74) or death (hazard ratio, 0.63; 95% CI, 0.31 to 1.30) (Figs. S2 and S3).</div><div role="paragraph">The most common reasons for an unfavorable status (after month 4) were death from any cause (in 7 participants in the 4-month group and 12 in the 6-month group) and treatment failure (in 9 and 5 participants, respectively). Among participants with treatment failure, 2 (both in the 4-month group) had a treatment extension, 2 (1 in each group) stopped treatment and had their treatment course restarted from the beginning during the first 8 weeks, and 10 (6 in the 4-month group and 4 in the 6-month group) had recurrence of tuberculosis (<a href="#t2">Table 2</a>).</div></section><section id="sec-2-4"><h3>Key Secondary Analysis</h3><div role="paragraph">The key secondary analysis included 958 participants who had been independently adjudicated to have tuberculosis at baseline (80% of the enrolled population); 910 of these participants were included in the modified intention-to-treat population. Of these 910 participants, 440 of 450 (98%) in the 4-month group and 447 of 460 (97%) in the 6-month group had a favorable outcome. The adjusted absolute difference in the risk of an unfavorable status in the 4-month group as compared with the 6-month group was −0.6 percentage points (95% CI, −2.6 to 1.4). In the per-protocol analysis, the difference was −1.1 percentage points (95% CI, −3.1 to 0.9) (<a href="#f2">Figure 2</a>). Results for the modified intention-to-treat efficacy outcome according to prespecified subgroup analyses (HIV status, region, sex, age, weight band, tuberculosis type, bacteriologic confirmation, and ethambutol given at baseline) were all consistent with the primary result (Fig. S4 and Table S8).</div></section><section id="sec-2-5"><h3>Adverse Events</h3><div role="paragraph"><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-c three-d">A total of 115 adverse events of grade 3 or higher occurred during treatment or up to 30 days after treatment in 95 participants (8% of all the children enrolled in the trial; 49 events in 47 participants in the 4-month group and 66 events in 48 participants in the 6-month group). Of these 115 adverse events, the most common were pneumonia or other chest infection (29 events [25%]) or liver-related events (11 [10%]); the incidences were similar in the two groups (<a href="#t3">Table 3</a> and S3).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t3.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/32491ffa-8218-4cbf-aab7-6a69787c67eb/assets/images/large/nejmoa2104535_t3.jpg" height="2434" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">4-Month Treatment<br>(N=602)</th><th class="txxx-borders">6-Month Treatment<br>(N=602)</th><th class="txxr-borders">Total<br>(N=1204)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Primary safety outcome — no. of events</td><td class="xxxx-borders shading">49</td><td class="xxxx-borders shading">66</td><td class="xxxr-borders shading">115</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of participants with ≥1 event (%)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">47 (8)</td><td class="xxxx-borders">48 (8)</td><td class="xxxr-borders">95 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At ≤4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of adverse events of grade ≥3</td><td class="xxxx-borders">35</td><td class="xxxx-borders">52</td><td class="xxxr-borders">87</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xxxx-borders shading">33 (5)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">73 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At &gt;4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of adverse events of grade ≥3</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">14</td><td class="xxxr-borders shading">28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xxxx-borders">14 (2)</td><td class="xxxx-borders">12 (2)</td><td class="xxxr-borders">26 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Serious adverse event — no. of events</td><td class="xxxx-borders shading">88</td><td class="xxxx-borders shading">104</td><td class="xxxr-borders shading">192</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">75 (12)</td><td class="xxxx-borders">75 (12)</td><td class="xxxr-borders">150 (12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At ≤4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">No. of serious adverse events</td><td class="xxxx-borders">35</td><td class="xxxx-borders">50</td><td class="xxxr-borders">85</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)</td><td class="xxxx-borders shading">33 (5)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">73 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At &gt;4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of serious adverse events</td><td class="xxxx-borders shading">53</td><td class="xxxx-borders shading">54</td><td class="xxxr-borders shading">107</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)</td><td class="xxxx-borders">47 (8)</td><td class="xxxx-borders">44 (7)</td><td class="xxxr-borders">91 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Death — no. (%)</td><td class="xxxx-borders shading">12 (2)</td><td class="xxxx-borders shading">19 (3)</td><td class="xxxr-borders shading">31 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At ≤4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of deaths (%)</td><td class="xxxx-borders shading">5 (1)</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxr-borders shading">11 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of deaths considered to be related to tuberculosis (%)</td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxr-borders">5 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At &gt;4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of deaths (%)</td><td class="xxxx-borders">7 (1)</td><td class="xxxx-borders">13 (2)</td><td class="xxxr-borders">20 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of deaths considered to be related to tuberculosis (%)</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxr-borders shading">8 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Adverse drug reaction — no. of participants (%)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">6 (1)</td><td class="xxxx-borders">11 (2)</td><td class="xxxr-borders">17 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Bacterial infection leading to hospitalization — no. of events</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">40</td><td class="xxxr-borders shading">80</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xbxx-borders">36 (6)</td><td class="xbxx-borders">30 (5)</td><td class="xbxr-borders">66 (5)</td></tr></tbody></table></div><figcaption><div class="caption">Primary Safety Outcome, Serious Adverse Events, Deaths, Adverse Drug Reactions, and Suspected Bacterial Infections Leading to Hospitalization.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events was used for grading the severity of adverse events. The primary safety outcome was an adverse event of grade 3 or higher that occurred during treatment and up to 30 days after the last dose of a trial drug. Serious adverse events were defined with the use of International Council for Harmonisation and Good Clinical Practice definitions as an adverse event that resulted in death, was life-threatening, led to hospitalization or prolonged existing hospitalization, resulted in persistent or clinically significant disability or incapacity, consisted of a congenital anomaly or birth defect, or was considered to be another important medical condition.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Participants may have had events both before and after the 4-month breakdown.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Adverse drug reactions during treatment and within 30 days after completion of treatment were assessed by the site investigator as being possibly, probably, or definitely related to the trial drugs. Further information on the adverse drug reactions, including event types and information on treatment discontinuations, is provided in Table S4.</div></div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-three-b"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-b">A total of 192 serious adverse events occurred in 150 participants (12%) in the trial, including 31 deaths (12 in the 4-month group and 19 in the 6-month group). Twenty deaths (7 in the 4-month group and 13 in the 6-month group) occurred after month 4, and 13 deaths (5 in the 4-month group and 8 in the 6-month group) were considered by the end-point review committee to be related to tuberculosis. Of the 31 deaths, 25 were in children younger than 2 years of age (Table S5).</span> Hospitalization for a respiratory bacterial infection occurred in 66 participants (5%), with 45 participants (26 in the 4-month group and 19 in the 6-month group) being hospitalized after month 4 (<a href="#t3">Table 3</a>).</div><div role="paragraph"><a id="exam-tint-three-a"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a">A total of 15 adverse drug reactions of grade 3 or 4 were considered by the investigators to be possibly, probably, or definitely related to trial drugs. These adverse reactions included 11 hepatic events. All the adverse reactions except 2 occurred during the first 8 weeks of therapy (Table S4).</span> Two participants permanently discontinued therapy after treatment interruption for an adverse reaction. None of the adverse reactions led to death.</div></section><section id="sec-2-6"><h3>Cost-Effectiveness Analysis</h3><div role="paragraph">A cost-effectiveness analysis showed that at 72 weeks, participants who had been treated for 4 months had similar health outcomes as those who had been treated for 6 months but with lower health care costs. A regression analysis controlling for chance differences in demographic characteristics and symptom severity estimated that the number of quality-adjusted life-years was similar in the two groups (mean difference, 0.003; 95% CI, −0.009 to 0.014) and that health care costs (assessed in 2019) were $17.34 (95% CI, 3.77 to 30.91) lower per child in the 4-month group (Table S7).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-d"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-d">The SHINE trial evaluated the duration of antituberculosis treatment in children with nonsevere, drug-susceptible tuberculosis who were living in countries with a high burden of tuberculosis, where nearly 90% of cases of tuberculosis in children occur.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> The trial showed the noninferiority of 4 months as compared with the standard 6 months of treatment, with the upper boundary of the 95% confidence interval being below the prespecified margin of 6 percentage points. Consistency of results across all the analyses, including a key secondary analysis in a subgroup of children who were adjudicated to have tuberculosis at baseline, was observed.</span> Participants had a good response to treatment with few adverse drug reactions, most of which occurred before 4 months, during the period when the two trial groups had the same treatment regimen.</div><div role="paragraph">Shortening treatment for drug-susceptible tuberculosis is a key goal for both adults and children. Early trials showed that it was possible to shorten the treatment duration in adults with culture-negative disease.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21 r22" id="body-ref-r22" href-manipulated="true">20-22</a></sup> A meta-analysis of treatment-duration trials involving adults showed that 4-month drug regimens were efficacious in adults with paucibacillary tuberculosis who had disease with a sputum-smear grade of less than 2+ (&lt;1 acid-fast bacillus per field) or noncavity disease.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> Recently, the Tuberculosis Trials Consortium Study 31/AIDS Clinical Trials Group A5349 trial showed the noninferiority of a 4-month rifapentine-based regimen containing moxifloxacin, as compared with the 6-month standard regimen, for all forms of drug-susceptible tuberculosis (including cavity disease) in adults and adolescents.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Challenges remain in terms of the availability of child-friendly formulations of rifapentine and moxifloxacin, data on doses in children, and cost. However, our results show that a new regimen with new drugs is not necessary for the shortening of treatment in the majority of children with drug-susceptible tuberculosis, since such treatment shortening can be accomplished with the affordable, child-friendly, fixed-dose combinations that are already available.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup></div><div role="paragraph">This trial showed the feasibility of identifying children with nonsevere disease. We used a pragmatic approach by following routine screening procedures and reviewing chest radiographs to assess the severity of respiratory tuberculosis. Despite perceived difficulties of obtaining respiratory samples in children, such challenges were overcome with appropriate training, and samples were successfully obtained for tuberculosis testing in all 1204 children who underwent randomization. The trial included children with HIV infection as well as those without HIV infection, with consistent results.</div><div role="paragraph">Most children with tuberculosis have paucibacillary and nonsevere disease with low rates of microbiologic tuberculosis confirmation in routine care. To ensure the applicability of our results to clinical practice and the spectrum of disease that is most prevalent in children, we did not limit the trial to bacteriologically confirmed tuberculosis. We adapted the pediatric consensus algorithm for diagnosis of intrathoracic tuberculosis<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-2" href-manipulated="true" aria-label="Reference 13">13</a></sup> to both intrathoracic tuberculosis and peripheral lymph-node tuberculosis and used independent expert review and central reading of chest radiographs, with blinding to the treatment assignments, to ensure objective categorization of tuberculosis status. The end-point review committee, whose members were unaware of the randomized group assignments, reviewed tuberculosis outcomes to minimize the effect of treatment assignment on adjudication.</div><div role="paragraph">Our trial had several strengths. It was well-powered, and we observed 94% adherence (to the receipt of ≥80% of the doses) in the assigned groups and 95% retention of trial participants, findings that increase confidence in the results. We assumed in the sample-size calculation that 8% of the participants in the 6-month group would have an unfavorable status, and we observed this result in 7% of the participants overall in the trial. However, events in 3% of the participants occurred after month 4, when the trial groups were receiving different durations of the treatment, which we had not anticipated when we designed the trial.</div><div role="paragraph">The trial also has several limitations. One limitation is that this trial was open-label, which had the potential to result in more frequent treatment extensions in the 4-month group, contributing to more unfavorable outcomes in this group. Despite this possible disadvantage in the 4-month group, the results showed consistently that the 4-month regimen was as good as the 6-month regimen. Another limitation relates to the generalizability of our results to settings where chest radiographs are not available for characterizing nonsevere tuberculosis.</div><div role="paragraph">Our inclusion criteria for the trial required smear microscopy to be undertaken to rule out more severe forms of respiratory tuberculosis. With the current rollout of rapid molecular diagnostic tests replacing smear microscopy,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> this may pose a challenge to implementation on the basis of the trial results. However, smear-grade and Xpert semiquantitative results have been shown to be correlated.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup> In our trial, most Xpert results from respiratory samples were negative and the few positive Xpert samples had low or very low semiquantitative results, which suggest that the trial findings can be extrapolated to settings where Xpert is replacing smear testing and that children with negative, low, or very low positive values on Xpert testing can be categorized as having nonsevere tuberculosis. It will be useful in future implementation studies to explore treatment shortening in all children who are treated for nonsevere, drug-susceptible tuberculosis, regardless of smear or Xpert results.</div><div role="paragraph">In this trial, we found that 4 months of antituberculosis treatment was noninferior to 6 months of therapy in children with drug-susceptible, nonsevere, smear-negative tuberculosis. The results suggest that a stratified medicine approach as an alternative to the one-size-fits-all strategy of treatment for presumptive drug-susceptible tuberculosis could be implemented in children with nonsevere tuberculosis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was updated on March 18, 2022, at NEJM.org.</div><div data-type="version-of-record" role="paragraph">This is the <i>New England Journal of Medicine</i> version of record, which includes all <i>Journal</i> editing and enhancements. The Author Final Manuscript, which is the author’s version after external peer review and before publication in the <i>Journal</i>, is available under a CC BY license at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612496" target="_blank">PMC7612496</a>.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (MR/L004445/1) from the U.K. Medical Research Council (<span class="named-content" data-type="funder">MRC</span>) and the Department for International Development (DFID) <span class="named-content" data-type="funder">Wellcome</span> <span class="named-content" data-type="funder">NIHR Joint Global Health Trials</span>, by a U.K. Research and Innovation Covid-19 Grant Extension Allocation Award, by a U.K. Research and Innovation <span class="named-content" data-type="funder">MRC</span> grant (MC_UU_00004/04, to Drs. Turkova and Crook), and by a Clinician Scientist Fellowship (to Dr. Seddon), jointly funded by the <span class="named-content" data-type="funder">MRC</span> and the Department for International Development under an <span class="named-content" data-type="funder">MRC</span>–DFID Concordat agreement (MR/R007942/1). <span class="named-content" data-type="funder">TB Alliance</span> provided support for drug purchase.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the children who participated in the SHINE trial and their caregivers; the nursing, pharmacy, and laboratory staff; all those who advised, volunteered, or otherwise supported community engagement at the trial sites; and the members of the trial steering committee, the end-point review committee, and the independent data monitoring committee for their contributions, including oversight of the safety of the trial.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2104535_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104535/suppl_file/nejmoa2104535_protocol.pdf" download="nejmoa2104535_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104535_protocol.pdf" data-doi="10.1056/NEJMoa2104535">Download</a></li><li>4.17 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2104535_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104535/suppl_file/nejmoa2104535_appendix.pdf" download="nejmoa2104535_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104535_appendix.pdf" data-doi="10.1056/NEJMoa2104535">Download</a></li><li>645.50 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2104535_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104535/suppl_file/nejmoa2104535_disclosures.pdf" download="nejmoa2104535_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104535_disclosures.pdf" data-doi="10.1056/NEJMoa2104535">Download</a></li><li>478.03 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2104535_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2104535/suppl_file/nejmoa2104535_data-sharing.pdf" download="nejmoa2104535_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2104535_data-sharing.pdf" data-doi="10.1056/NEJMoa2104535">Download</a></li><li>69.68 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">WHO Global Tuberculosis Programme. Global tuberculosis report 2021. Geneva: World Health Organization, 2021 (<a href="https://www.who.int/publications/digital/global-tuberculosis-report-2021" target="_blank">https://www.who.int/publications/digital/global-tuberculosis-report-2021</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2021&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. <em>Lancet Glob Health</em> 2017;5(9):e898-e906.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2214-109X(17)30289-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28807188/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+global+burden+of+tuberculosis+mortality+in+children%3A+a+mathematical+modelling+study.&amp;publication_year=2017&amp;journal=Lancet+Glob+Health&amp;pages=e898-e906&amp;doi=10.1016%2FS2214-109X%2817%2930289-9&amp;pmid=28807188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. <em>Pediatr Infect Dis J</em> 2012;31:347-352.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/INF.0b013e318243e27b" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22315002/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302696600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+proposed+comprehensive+classification+of+tuberculosis+disease+severity+in+children.&amp;publication_year=2012&amp;journal=Pediatr+Infect+Dis+J&amp;pages=347-352&amp;doi=10.1097%2FINF.0b013e318243e27b&amp;pmid=22315002" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] nonsevere, smear-negative tuberculosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for severe respiratory tuberculosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. <em>Int J Tuberc Lung Dis</em> 2006;10:732-738.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16848333/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238718400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+spectrum+of+disease+in+children+treated+for+tuberculosis+in+a+highly+endemic+area.&amp;publication_year=2006&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=732-738&amp;pmid=16848333" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Loveday M, Sunkari B, Marais BJ, Master I, Brust JC. Dilemma of managing asymptomatic children referred with ‘culture-confirmed’ drug-resistant tuberculosis. <em>Arch Dis Child</em> 2016;101:608-613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/archdischild-2015-310186" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27044259/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378065400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dilemma+of+managing+asymptomatic+children+referred+with+%E2%80%98culture-confirmed%E2%80%99+drug-resistant+tuberculosis.&amp;publication_year=2016&amp;journal=Arch+Dis+Child&amp;pages=608-613&amp;doi=10.1136%2Farchdischild-2015-310186&amp;pmid=27044259" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. <em>J Infect Dis</em> 2012;206:1809-1815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jis608" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23033147/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311667400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Childhood+tuberculosis+and+malnutrition.&amp;publication_year=2012&amp;journal=J+Infect+Dis&amp;pages=1809-1815&amp;doi=10.1093%2Finfdis%2Fjis608&amp;pmid=23033147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Martinez L, Cords O, Horsburgh CR, Andrews JR; Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. <em>Lancet</em> 2020;395:973-984.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30166-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32199484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521744600028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+risk+of+tuberculosis+in+children+after+close+exposure%3A+a+systematic+review+and+individual-participant+meta-analysis.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=973-984&amp;doi=10.1016%2FS0140-6736%2820%2930166-5&amp;pmid=32199484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rapid+advice%3A+treatment+of+tuberculosis+in+children&amp;publication_year=2010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Graham SM, Grzemska M, Gie RP. The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. <em>Int J Tuberc Lung Dis</em> 2015;19:Suppl 1:3-8.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.15.0416" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26564534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365837300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+background+and+rationale+for+a+new+fixed-dose+combination+for+first-line+treatment+of+tuberculosis+in+children.&amp;publication_year=2015&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=3-8&amp;doi=10.5588%2Fijtld.15.0416&amp;pmid=26564534" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization, 2014.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidance+for+national+tuberculosis+programmes+on+the+management+of+tuberculosis+in+children&amp;publication_year=2014" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] revised doses and became available in 2015. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] using WHO-recommended pediatric doses. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] with the use of child-friendly formulations </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. <em>Trials</em> 2018;19:237-237.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-018-2608-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29673395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430599800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Shorter+treatment+for+minimal+tuberculosis+%28TB%29+in+children+%28SHINE%29%3A+a+study+protocol+for+a+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Trials&amp;pages=237-237&amp;doi=10.1186%2Fs13063-018-2608-5&amp;pmid=29673395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative Reference Case for economic evaluation: an aid to thought. <em>Value Health</em> 2016;19:921-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jval.2016.04.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27987641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396448300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+International+Decision+Support+Initiative+Reference+Case+for+economic+evaluation%3A+an+aid+to+thought.&amp;publication_year=2016&amp;journal=Value+Health&amp;pages=921-928&amp;doi=10.1016%2Fj.jval.2016.04.015&amp;pmid=27987641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. <em>Clin Infect Dis</em> 2015;61:Suppl 3:S179-S187.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ581" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26409281/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362952900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+case+definitions+for+classification+of+intrathoracic+tuberculosis+in+children%3A+an+update.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S179-S187&amp;doi=10.1093%2Fcid%2Fciv581&amp;pmid=26409281" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] clinical, radiologic, and laboratory data. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for diagnosis of intrathoracic tuberculosis </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Wills GH, Graham SM, Seddon JA, et al. A method for baseline adjudication of tuberculosis diagnosis in children in a therapeutic clinical trial: experience from SHINE. Proceedings and abstracts of the 51st Union World Conference on Lung Health, October 20–24, 2020. Paris: the International Union against Tuberculosis and Lung Disease, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+method+for+baseline+adjudication+of+tuberculosis+diagnosis+in+children+in+a+therapeutic+clinical+trial%3A+experience+from+SHINE&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. November 2014 (<a href="https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf">https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+%28DAIDS%29+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events.+Version+2.0&amp;publication_year=2014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Wademan DT, Busakwe L, Nicholson TJ, et al. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. <em>Int J Tuberc Lung Dis</em> 2019;23:1263-1268.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.19.0115" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31931909/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502329600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Acceptability+of+a+first-line+anti-tuberculosis+formulation+for+children%3A+qualitative+data+from+the+SHINE+trial.&amp;publication_year=2019&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=1263-1268&amp;doi=10.5588%2Fijtld.19.0115&amp;pmid=31931909" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Floyd K, Glaziou P, Sismanidis C, et al. Global tuberculosis report 2012. Geneva: World Health Organization, 2012.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2012&amp;publication_year=2012" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Kekitiinwa A, Cook A, Nathoo K, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. <em>Lancet</em> 2013;381:1391-1403.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)62198-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23473847/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317894800036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Routine+versus+clinically+driven+laboratory+monitoring+and+first-line+antiretroviral+therapy+strategies+in+African+children+with+HIV+%28ARROW%29%3A+a+5-year+open-label+randomised+factorial+trial.&amp;publication_year=2013&amp;journal=Lancet&amp;pages=1391-1403&amp;doi=10.1016%2FS0140-6736%2812%2962198-9&amp;pmid=23473847" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">WHO Global Tuberculosis Programme. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2019&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. <em>Ann Acad Med Singap</em> 2002;31:175-181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.47102/annals-acadmedsg.V31N2p175" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11957554/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000174808900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+chemotherapy+in+the+treatment+of+smear-negative+pulmonary+tuberculosis%3A+results+at+30+to+60+months.&amp;publication_year=2002&amp;journal=Ann+Acad+Med+Singap&amp;pages=175-181&amp;doi=10.47102%2Fannals-acadmedsg.V31N2p175&amp;pmid=11957554" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Hong Kong Chest Service, Madras Tuberculosis Research Centre, British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 5 years. <em>Am Rev Respir Dis</em> 1989;139:871-876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/ajrccm/139.4.871" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2648911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+3-month%2C+4-month%2C+and+6-month+regimens+of+chemotherapy+for+sputum-smear-negative+pulmonary+tuberculosis%3A+results+at+5+years.&amp;publication_year=1989&amp;journal=Am+Rev+Respir+Dis&amp;pages=871-876&amp;doi=10.1164%2Fajrccm%2F139.4.871&amp;pmid=2648911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Hong Kong Chest Service, Madras Tuberculosis Research Centre, British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 60 months. <em>Am Rev Respir Dis</em> 1984;130:23-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6377997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SZ87500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+2-month%2C+3-month%2C+and+12-month+regimens+of+chemotherapy+for+sputum-smear-negative+pulmonary+tuberculosis%3A+results+at+60+months.&amp;publication_year=1984&amp;journal=Am+Rev+Respir+Dis&amp;pages=23-28&amp;pmid=6377997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. <em>Nat Med</em> 2018;24:1708-1715.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0224-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30397355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449404200023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+patient-level+pooled+analysis+of+treatment-shortening+regimens+for+drug-susceptible+pulmonary+tuberculosis.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=1708-1715&amp;doi=10.1038%2Fs41591-018-0224-2&amp;pmid=30397355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. <em>N Engl J Med</em> 2021;384:1705-1718.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104535&amp;key=10.1056%2FNEJMoa2033400&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33951360/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000647698500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+rifapentine+regimens+with+or+without+moxifloxacin+for+tuberculosis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1705-1718&amp;doi=10.1056%2FNEJMoa2033400&amp;pmid=33951360" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Global Alliance for TB Drug Development. New milestone for children with tuberculosis reached as one million treatments of child-friendly medicines are ordered. June 18, 2019 (<a href="https://www.tballiance.org/news/one-million-child-friendly-tuberculosis-medicines">https://www.tballiance.org/news/one-million-child-friendly-tuberculosis-medicines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+milestone+for+children+with+tuberculosis+reached+as+one+million+treatments+of+child-friendly+medicines+are+ordered&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis — rapid diagnostics for tuberculosis detection. July 7, 2021 (<a href="https://www.who.int/publications/i/item/9789240029415">https://www.who.int/publications/i/item/9789240029415</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=WHO+consolidated+guidelines+on+tuberculosis.+Module+3%3A+diagnosis+%E2%80%94+rapid+diagnostics+for+tuberculosis+detection&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. <em>Am J Respir Crit Care Med</em> 2011;184:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201103-0536OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21836139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296613900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multisite+assessment+of+the+quantitative+capabilities+of+the+Xpert+MTB%2FRIF+assay.&amp;publication_year=2011&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1076-1084&amp;doi=10.1164%2Frccm.201103-0536OC&amp;pmid=21836139" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/10"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">10</span></span> • <span property="datePublished">March 10, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">911</span>-<span property="pageEnd">922</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 9, 2022</div><div><b class="core-label">Published in issue</b>: March 10, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/childhood-diseases" alt="View article keyword Childhood Diseases" data-interactiontype="article_recirculation_click">Childhood Diseases</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/diagnostics" alt="View article keyword Diagnostics" data-interactiontype="article_recirculation_click">Diagnostics</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/tuberculosis" alt="View article keyword Tuberculosis" data-interactiontype="article_recirculation_click">Tuberculosis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Turkova</span>, <span property="honorificSuffix">M.R.C.P.C.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Genevieve H.</span> <span property="familyName">Wills</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eric</span> <span property="familyName">Wobudeya</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chishala</span> <span property="familyName">Chabala</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Megan</span> <span property="familyName">Palmer</span>, <span property="honorificSuffix">M.B., Ch.B., M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Aarti</span> <span property="familyName">Kinikar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Syed</span> <span property="familyName">Hissar</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Louise</span> <span property="familyName">Choo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philippa</span> <span property="familyName">Musoke</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Veronica</span> <span property="familyName">Mulenga</span>, <span property="honorificSuffix">M.Med., M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vidya</span> <span property="familyName">Mave</span>, <span property="honorificSuffix">M.D., M.P.H.&amp;T.M.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bency</span> <span property="familyName">Joseph</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kristen</span> <span property="familyName">LeBeau</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Margaret J.</span> <span property="familyName">Thomason</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert B.</span> <span property="familyName">Mboizi</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Monica</span> <span property="familyName">Kapasa</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marieke M.</span> <span property="familyName">van der Zalm</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Priyanka</span> <span property="familyName">Raichur</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Perumal K.</span> <span property="familyName">Bhavani</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Helen</span> <span property="familyName">McIlleron</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anne-Marie</span> <span property="familyName">Demers</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rob</span> <span property="familyName">Aarnoutse</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James</span> <span property="familyName">Love-Koh</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James A.</span> <span property="familyName">Seddon</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Steven B.</span> <span property="familyName">Welch</span>, <span property="honorificSuffix">F.R.C.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stephen M.</span> <span property="familyName">Graham</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anneke C.</span> <span property="familyName">Hesseling</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Diana M.</span> <span property="familyName">Gibb</span>, <span property="honorificSuffix">M.B., Ch.B., M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Angela M.</span> <span property="familyName">Crook</span>, <span property="honorificSuffix">Ph.D.</span></span>, for <span property="author" typeof="Person">the SHINE Trial Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Medical Research Council Clinical Trials Unit, University College London (A.T., G.H.W., L.C., K.L., M.J.T., D.M.G., A.M.C.), and the Department of Infectious Diseases, Imperial College London (J.A.S.), London, the Centre for Health Economics, University of York, York (J.L.-K.), and the Department of Paediatrics, Birmingham Chest Clinic and Heartlands Hospital, University Hospitals Birmingham, Birmingham (S.B.W.) — all in the United Kingdom; Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda (E.W., P.M., R.B.M.); University Teaching Hospital, Lusaka, Zambia (C.C., V. Mulenga, M.K.); Desmond Tutu TB Centre, the Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch (M.P., M.M.Z., A.-M.D., J.A.S., A.C.H.), and the Division of Clinical Pharmacology, University of Cape Town, Cape Town (H.M.) — both in South Africa; B.J. Medical College, Pune (A.K., V. Mave, P.R.), and the National Institute for Research in Tuberculosis, Chennai (S.H., B.J., P.K.B.) — both in India; Radboud University Medical Center, Nijmegen, the Netherlands (R.A.); the Centre for International Child Health, Department of Paediatrics, University of Melbourne, and Murdoch Children’s Research Institute, Royal Children’s Hospital — both in Melbourne, VIC, Australia (S.M.G.); and the International Union against Tuberculosis and Lung Disease, Paris (S.M.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Turkova can be contacted at <a href="mailto:a.turkova@ucl.ac.uk">a.turkova@ucl.ac.uk</a> or at the Medical Research Council Clinical Trials Unit, University College London, 90 High Holborn, London WC1V 6LJ, United Kingdom.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The members of the SHINE Trial Team are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Gibb and Crook contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">133</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2104535" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="4fdeda34-dbbf-aaaa-1043-0679843845f6"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166" style="display:inline-block;">
                <img alt="Article has an altmetric score of 425" src="https://badges.altmetric.com/?size=320&amp;score=425&amp;types=mbvctfd1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_4fdeda34-dbbf-aaaa-1043-0679843845f6" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=news">
          Picked up by <b>41</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=twitter">
          Posted by <b>172</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=124375166&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>286</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="9523b0aab351010f-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2104535"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2104535%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="133" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John W. Wilson, </li><li class="list-inline-item cited-by__entry__author">Zelalem Temesgen, </li><li class="list-inline-item cited-by__entry__author">James T. Gaensbauer, </li></ul><span class="cited-by__entry__title">Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis, </span><span class="cited-by__entry__series-title">Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, </span><span class="cited-by__entry__volume"><strong>40</strong>, </span><span class="cited-by__entry__page-range">(100536), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jctube.2025.100536" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jctube.2025.100536</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jctube.2025.100536" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">T. Nkomo, </li><li class="list-inline-item cited-by__entry__author">Z. Udwadia, </li><li class="list-inline-item cited-by__entry__author">D. Vambe, </li><li class="list-inline-item cited-by__entry__author">A. van Rie, </li><li class="list-inline-item cited-by__entry__author">S.S. Thi, </li><li class="list-inline-item cited-by__entry__author">J. Stillo, </li><li class="list-inline-item cited-by__entry__author">A. Stambekova, </li><li class="list-inline-item cited-by__entry__author">A. Sinha, </li><li class="list-inline-item cited-by__entry__author">M.L. Rich, </li><li class="list-inline-item cited-by__entry__author">A. Reuter, </li><li class="list-inline-item cited-by__entry__author">J. Patel, </li><li class="list-inline-item cited-by__entry__author">R. Otto-Knapp, </li><li class="list-inline-item cited-by__entry__author">I. Motta, </li><li class="list-inline-item cited-by__entry__author">A. Mesic, </li><li class="list-inline-item cited-by__entry__author">L. McKenna, </li><li class="list-inline-item cited-by__entry__author">S. Maru, </li><li class="list-inline-item cited-by__entry__author">E. Lessem, </li><li class="list-inline-item cited-by__entry__author">C. Lange, </li><li class="list-inline-item cited-by__entry__author">N. Kiria, </li><li class="list-inline-item cited-by__entry__author">Y. Kherabi, </li><li class="list-inline-item cited-by__entry__author">G. Günther, </li><li class="list-inline-item cited-by__entry__author">L. Guglielmetti, </li><li class="list-inline-item cited-by__entry__author">T. Decroo, </li><li class="list-inline-item cited-by__entry__author">L. Chen, </li><li class="list-inline-item cited-by__entry__author">A. Ashesh, </li><li class="list-inline-item cited-by__entry__author">A. Abubakirov, </li><li class="list-inline-item cited-by__entry__author">J. Furin, </li></ul><span class="cited-by__entry__title">Clinical best practices for caring for people with expanded resistance to newer TB drugs, </span><span class="cited-by__entry__series-title">IJTLD OPEN, </span><span class="cited-by__entry__volume"><strong>2</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(315-323), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.5588/ijtldopen.25.0240" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.5588/ijtldopen.25.0240</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.5588/ijtldopen.25.0240" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nusrat Shafiq, </li><li class="list-inline-item cited-by__entry__author">Ashok Kumar, </li><li class="list-inline-item cited-by__entry__author">Vikram Vohra, </li><li class="list-inline-item cited-by__entry__author">Gopal Krishan Khuller, </li><li class="list-inline-item cited-by__entry__author">Manjula Singh, </li><li class="list-inline-item cited-by__entry__author">Amandeep Kaur, </li><li class="list-inline-item cited-by__entry__author">Narinder Gulati, </li><li class="list-inline-item cited-by__entry__author">Vishal Chopra, </li><li class="list-inline-item cited-by__entry__author">Aditi Gupta, </li><li class="list-inline-item cited-by__entry__author">Sandeep Kaushal, </li><li class="list-inline-item cited-by__entry__author">Akashdeep Singh, </li><li class="list-inline-item cited-by__entry__author">A N Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Ritin Mohindra, </li><li class="list-inline-item cited-by__entry__author">Rajesh Raju, </li><li class="list-inline-item cited-by__entry__author">Honney Sawhney, </li><li class="list-inline-item cited-by__entry__author">Divya Goel, </li><li class="list-inline-item cited-by__entry__author">Alkesh Kumar Khurana, </li><li class="list-inline-item cited-by__entry__author">Sagar Khadanga, </li><li class="list-inline-item cited-by__entry__author">Ashok Bansal, </li><li class="list-inline-item cited-by__entry__author">Pavan Malhotra, </li><li class="list-inline-item cited-by__entry__author">Anil K Gupta, </li><li class="list-inline-item cited-by__entry__author">Dinesh Kansal, </li><li class="list-inline-item cited-by__entry__author">Devendra Singh Dadhwal, </li><li class="list-inline-item cited-by__entry__author">Sunil Sethi, </li><li class="list-inline-item cited-by__entry__author">Varinder K Saini, </li><li class="list-inline-item cited-by__entry__author">Deepak Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Parvinder Jit Singh, </li><li class="list-inline-item cited-by__entry__author">Madhu Sabharwal, </li><li class="list-inline-item cited-by__entry__author">Lokender Kumar, </li><li class="list-inline-item cited-by__entry__author">Khalid Umer Khayyam, </li><li class="list-inline-item cited-by__entry__author">Dipti Kushwaha, </li><li class="list-inline-item cited-by__entry__author">Vidhu Mittal, </li><li class="list-inline-item cited-by__entry__author">Samriti Jain, </li><li class="list-inline-item cited-by__entry__author">Bharath A Chhabria, </li><li class="list-inline-item cited-by__entry__author">Sandeep Kaur, </li><li class="list-inline-item cited-by__entry__author">Abhishek Taneja, </li><li class="list-inline-item cited-by__entry__author">Prashant Pathak, </li><li class="list-inline-item cited-by__entry__author">Abhinav Gupta, </li><li class="list-inline-item cited-by__entry__author">Rajat Bral, </li><li class="list-inline-item cited-by__entry__author">Ajay Kumar, </li><li class="list-inline-item cited-by__entry__author">Ritika Kondel Bhandari, </li><li class="list-inline-item cited-by__entry__author">Avaneesh Kumar Pandey, </li><li class="list-inline-item cited-by__entry__author">Imraan Rather, </li><li class="list-inline-item cited-by__entry__author">Samir Malhotra, </li></ul><span class="cited-by__entry__title">Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial, </span><span class="cited-by__entry__series-title">Journal of Antimicrobial Chemotherapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/jac/dkaf176" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/jac/dkaf176</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/jac/dkaf176" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lisa Frigati, </li><li class="list-inline-item cited-by__entry__author">Leonore Greybe, </li><li class="list-inline-item cited-by__entry__author">Savvas Andronikou, </li><li class="list-inline-item cited-by__entry__author">Ernst Eber, </li><li class="list-inline-item cited-by__entry__author">Shyam Sunder B. Venkatakrishna, </li><li class="list-inline-item cited-by__entry__author">Pierre Goussard, </li></ul><span class="cited-by__entry__title">Respiratory infections in low and middle-income countries, </span><span class="cited-by__entry__series-title">Paediatric Respiratory Reviews, </span><span class="cited-by__entry__volume"><strong>54</strong>, </span><span class="cited-by__entry__page-range">(43-51), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prrv.2024.08.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prrv.2024.08.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prrv.2024.08.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Katie Wright, </li></ul><span class="cited-by__entry__title">Tackling Tuberculosis: The Current Landscape and Future Directions, </span><span class="cited-by__entry__series-title">EMJ Microbiology &amp; Infectious Diseases, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.33590/emjmicrobiolinfectdis/PBLK4850" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shijia Ge, </li><li class="list-inline-item cited-by__entry__author">Kui Liu, </li><li class="list-inline-item cited-by__entry__author">Xineng Jiang, </li><li class="list-inline-item cited-by__entry__author">Zhen Feng, </li><li class="list-inline-item cited-by__entry__author">Songhua Chen, </li><li class="list-inline-item cited-by__entry__author">Yaling Feng, </li><li class="list-inline-item cited-by__entry__author">Guoyong Jiang, </li><li class="list-inline-item cited-by__entry__author">Zhicheng Yu, </li><li class="list-inline-item cited-by__entry__author">Lingyun Song, </li><li class="list-inline-item cited-by__entry__author">Lingyun Shao, </li><li class="list-inline-item cited-by__entry__author">Yilin Zhang, </li><li class="list-inline-item cited-by__entry__author">Feng Sun, </li><li class="list-inline-item cited-by__entry__author">Tao Li, </li><li class="list-inline-item cited-by__entry__author">Bin Chen, </li><li class="list-inline-item cited-by__entry__author">Yang Li, </li><li class="list-inline-item cited-by__entry__author">Wenhong Zhang, </li></ul><span class="cited-by__entry__title">Prevalence, Progression, and Treatment of Asymptomatic Tuberculosis: A Prospective Cohort Study in Lanxi County, Zhejiang Province, China, </span><span class="cited-by__entry__series-title">Open Forum Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/ofid/ofaf275" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/ofid/ofaf275</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/ofid/ofaf275" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Brittney Sweetser, </li><li class="list-inline-item cited-by__entry__author">Esin Nkereuwem, </li><li class="list-inline-item cited-by__entry__author">Jascent Nakafeero, </li><li class="list-inline-item cited-by__entry__author">Marie Gomez, </li><li class="list-inline-item cited-by__entry__author">Peter Wambi, </li><li class="list-inline-item cited-by__entry__author">Moses Nsereko, </li><li class="list-inline-item cited-by__entry__author">Alfred Andama, </li><li class="list-inline-item cited-by__entry__author">Joel D Ernst, </li><li class="list-inline-item cited-by__entry__author">Adithya Cattamanchi, </li><li class="list-inline-item cited-by__entry__author">Beate Kampmann, </li><li class="list-inline-item cited-by__entry__author">Devan Jaganath, </li><li class="list-inline-item cited-by__entry__author">Eric Wobudeya, </li></ul><span class="cited-by__entry__title">A Prospective Evaluation of a Three-Gene Host Response Signature to Classify Tuberculosis Severity in Children, </span><span class="cited-by__entry__series-title">Journal of the Pediatric Infectious Diseases Society, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/jpids/piaf041" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/jpids/piaf041</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/jpids/piaf041" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Grace Muzanyi, </li><li class="list-inline-item cited-by__entry__author">Charles M. Bark, </li></ul><span class="cited-by__entry__title">Severe Tuberculosis, </span><span class="cited-by__entry__series-title">Medical Clinics of North America, </span><span class="cited-by__entry__volume"><strong>109</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(641-650), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.mcna.2024.12.001" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.mcna.2024.12.001</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.mcna.2024.12.001" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Vidya Mave, </li><li class="list-inline-item cited-by__entry__author">Mandar Paradkar, </li><li class="list-inline-item cited-by__entry__author">Francesca Conradie, </li><li class="list-inline-item cited-by__entry__author">Amita Gupta, </li><li class="list-inline-item cited-by__entry__author">Anchalee Avihingsanon, </li><li class="list-inline-item cited-by__entry__author">Graeme Meintjes, </li><li class="list-inline-item cited-by__entry__author">Anna Turkova, </li><li class="list-inline-item cited-by__entry__author">Kelly E Dooley, </li><li class="list-inline-item cited-by__entry__author">Richard E Chaisson, </li></ul><span class="cited-by__entry__title">Tuberculosis disease among people with HIV: therapeutic advances, </span><span class="cited-by__entry__series-title">The Lancet HIV, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(e367-e381), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S2352-3018(25)00040-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S2352-3018(25)00040-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S2352-3018(25)00040-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lorenzo Guglielmetti, </li><li class="list-inline-item cited-by__entry__author">Samiran Panda, </li><li class="list-inline-item cited-by__entry__author">Amanzhan Abubakirov, </li><li class="list-inline-item cited-by__entry__author">Naseem Salahuddin, </li><li class="list-inline-item cited-by__entry__author">Christophe Perrin, </li><li class="list-inline-item cited-by__entry__author">Carole D Mitnick, </li></ul><span class="cited-by__entry__title">Equitable, personalised medicine for tuberculosis: treating patients, not diseases, </span><span class="cited-by__entry__series-title">The Lancet Respiratory Medicine, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(382-385), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S2213-2600(25)00080-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S2213-2600(25)00080-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S2213-2600(25)00080-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2104535%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2104535" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2104535" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104535.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f1.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/43eede6a-d10d-4747-a447-8ac89094fe5f/assets/images/large/nejmoa2104535_f1.jpg" height="3438" width="2622" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization and Treatment of the Patients.</div><div class="notes"><div role="doc-footnote">All the eligible participants with tuberculosis (TB) initially received 8 weeks of standard therapy with isoniazid, rifampin, and pyrazinamide (fixed-dose combination formulation), with or without ethambutol according to local guidelines (intensive phase). This treatment was followed by standard therapy with isoniazid and rifampin (continuation phase) in a fixed-dose combination for either 8 weeks in the 4-month group (intervention) or 16 weeks in the 6-month group (control). MDR-TB denotes multidrug-resistant TB.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f2.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/ff43ac35-9290-4e67-85f4-534e13431073/assets/images/large/nejmoa2104535_f2.jpg" height="1115" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Unadjusted Analysis of the Primary Efficacy and Key Secondary Outcomes in the Trial Populations.</div><div class="notes"><div role="doc-footnote">The primary efficacy outcome was unfavorable status by 72 weeks, which was defined as a composite of treatment failure (treatment extension, change, or restart or tuberculosis recurrence), loss to follow-up during treatment, or death, with the exclusion of all the participants who had undergone randomization but did not complete 4 months of treatment (modified intention-to-treat population). The per-protocol population included all the participants in the modified intention-to-treat population except those who had not adhered to the trial regimen. The intention-to-treat population included all the participants who had undergone randomization. Differences have been carried to one decimal place because of the small values. The prespecified margin for noninferiority in the primary efficacy analysis was 6 percentage points (dashed line). The key secondary analysis was unfavorable status at 72 weeks as assessed among the 958 participants who had been independently adjudicated as having tuberculosis at baseline.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2104535/asset/08202639-4da3-4ffc-ba03-61f943dac5fc/assets/images/large/nejmoa2104535_t1.jpg" height="2188" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">4-Month Treatment<br>(N=602)</th><th class="txxx-borders">6-Month Treatment<br>(N=602)</th><th class="txxr-borders">Total<br>(N=1204)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (interquartile range) — yr</td><td class="xxxx-borders">3.4 (1.5 to 6.9)</td><td class="xxxx-borders">3.5 (1.5 to 7.1)</td><td class="xxxr-borders">3.5 (1.5 to 7.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">2 mo to 15 yr</td><td class="xxxx-borders shading">2 mo to 15 yr</td><td class="xxxr-borders shading">2 mo to 15 yr</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">297 (49)</td><td class="xxxx-borders">286 (48)</td><td class="xxxr-borders">583 (48)</td></tr><tr data-type="row"><td class="xxlx-borders shading">Site country — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Uganda</td><td class="xxxx-borders">188 (31)</td><td class="xxxx-borders">188 (31)</td><td class="xxxr-borders">376 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Zambia</td><td class="xxxx-borders shading">183 (30)</td><td class="xxxx-borders shading">181 (30)</td><td class="xxxr-borders shading">364 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">South Africa</td><td class="xxxx-borders">156 (26)</td><td class="xxxx-borders">159 (26)</td><td class="xxxr-borders">315 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">India</td><td class="xxxx-borders shading">75 (12)</td><td class="xxxx-borders shading">74 (12)</td><td class="xxxr-borders shading">149 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">HIV-positive status — no. (%)</td><td class="xxxx-borders">65 (11)</td><td class="xxxx-borders">62 (10)</td><td class="xxxr-borders">127 (11)</td></tr><tr data-type="row"><td class="xxlx-borders shading">WHO weight band — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3–3.9 kg</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxr-borders">3 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4–7.9 kg</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxx-borders shading">92 (15)</td><td class="xxxr-borders shading">178 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">8–11.9 kg</td><td class="xxxx-borders">162 (27)</td><td class="xxxx-borders">152 (25)</td><td class="xxxr-borders">314 (26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">12–15.9 kg</td><td class="xxxx-borders shading">126 (21)</td><td class="xxxx-borders shading">116 (19)</td><td class="xxxr-borders shading">242 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">16–24.9 kg</td><td class="xxxx-borders">142 (24)</td><td class="xxxx-borders">153 (25)</td><td class="xxxr-borders">295 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥25 kg</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxx-borders shading">86 (14)</td><td class="xxxr-borders shading">172 (14)</td></tr><tr data-type="row"><td class="xxlx-borders">Clinical presentation — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Respiratory tuberculosis</td><td class="xxxx-borders shading">398 (66)</td><td class="xxxx-borders shading">406 (67)</td><td class="xxxr-borders shading">804 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mixed respiratory and peripheral lymph-node tuberculosis</td><td class="xxxx-borders">182 (30)</td><td class="xxxx-borders">171 (28)</td><td class="xxxr-borders">353 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral lymph-node tuberculosis</td><td class="xxxx-borders shading">19 (3)</td><td class="xxxx-borders shading">21 (3)</td><td class="xxxr-borders shading">40 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">7 (1)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><i>M. tuberculosis</i> culture and Xpert MTB/RIF testing results — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">All positive results</td><td class="xxxx-borders">85 (14)</td><td class="xxxx-borders">80 (13)</td><td class="xxxr-borders">165 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Tuberculosis culture–positive only</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">80 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Xpert MTB/RIF–positive only</td><td class="xxxx-borders">14 (2)</td><td class="xxxx-borders">5 (1)</td><td class="xxxr-borders">19 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Tuberculosis culture–positive and Xpert MTB/RIF–positive</td><td class="xbxx-borders shading">31 (5)</td><td class="xbxx-borders shading">35 (6)</td><td class="xbxr-borders shading">66 (5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">HIV denotes human immunodeficiency virus, and WHO World Health Organization.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">These participants did not have a cough for more than 2 weeks or one or more peripheral lymph nodes suggestive of tuberculosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Microbiologic confirmation was from respiratory samples (gastric aspirate or washing or induced or expectorated sputum) and fine-needle aspiration of enlarged lymph nodes and was defined as positive for <i>Mycobacterium tuberculosis</i> on culture or the Xpert MTB/RIF assay. Cultures were assessed with Löwenstein–Jensen solid-culture medium or a mycobacteria growth indicator tube with liquid culture system.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2104535/asset/7d59b833-5a60-4d19-b311-360df828c116/assets/images/large/nejmoa2104535_t2.jpg" height="1506" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">4-Month Treatment<br>(N=572)</th><th class="txxx-borders">6-Month Treatment<br>(N=573)</th><th class="txxr-borders" colspan="2"><span>Difference (95% CI)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">Adjusted Analysis<a href="#core-t2fn2" role="doc-noteref">†</a></th><th class="xxxr-borders">Unadjusted Analysis</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>percentage points</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Unfavorable status — no. (%)</td><td class="xxxx-borders shading">16 (3)</td><td class="xxxx-borders shading">18 (3)</td><td class="xxxx-borders shading">−0.4<br>(−2.2 to 1.5)</td><td class="xxxr-borders shading">−0.3<br>(−2.3 to 1.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death from any cause after 4 mo</td><td class="xxxx-borders">7 (1)</td><td class="xxxx-borders">12 (2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Loss to follow-up after 4 mo but during treatment period</td><td class="xxxx-borders shading">0<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Treatment failure</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Tuberculosis recurrence</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxx-borders shading">4 (1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Extension of treatment</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Restart of treatment<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Favorable status — no. (%)</td><td class="xbxx-borders">556 (97)</td><td class="xbxx-borders">555 (97)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The primary efficacy outcome was unfavorable status by 72 weeks. Unfavorable status was defined as a tuberculosis event (treatment failure, including treatment extension beyond the replacement of missed doses, drug changes or restarts in antituberculosis treatment due to suspected treatment failure, and tuberculosis recurrence as adjudicated by the end-point review committee, whose members were unaware of the treatment assignments), loss to follow-up during treatment, or death from any cause. Favorable status was defined as the completion of treatment and a status of being clinically well, without having had retreatment or another unfavorable outcome. The primary modified intention-to-treat population included all the participants who had undergone randomization except those who did not complete 4 months of treatment or who had a late exclusion (on the basis of data collated before randomization) and those who were clinically well after the completion of treatment but were subsequently lost to follow-up.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The analysis was adjusted with Cochran–Mantel–Haenszel weighting for trial center, participant age (&lt;3 years or ≥3 years), HIV status, and ethambutol use.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">None of the participants extended their treatment beyond 4 months and were subsequently lost to follow-up.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Two participants stopped treatment and had their treatment course restarted from the beginning during the first 8 weeks.</div></div></div></figcaption></a><figcaption><div class="caption">Primary Efficacy Analysis (Modified Intention-to-Treat Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2104535/asset/32491ffa-8218-4cbf-aab7-6a69787c67eb/assets/images/large/nejmoa2104535_t3.jpg" height="2434" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">4-Month Treatment<br>(N=602)</th><th class="txxx-borders">6-Month Treatment<br>(N=602)</th><th class="txxr-borders">Total<br>(N=1204)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Primary safety outcome — no. of events</td><td class="xxxx-borders shading">49</td><td class="xxxx-borders shading">66</td><td class="xxxr-borders shading">115</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of participants with ≥1 event (%)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">47 (8)</td><td class="xxxx-borders">48 (8)</td><td class="xxxr-borders">95 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At ≤4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of adverse events of grade ≥3</td><td class="xxxx-borders">35</td><td class="xxxx-borders">52</td><td class="xxxr-borders">87</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xxxx-borders shading">33 (5)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">73 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At &gt;4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of adverse events of grade ≥3</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">14</td><td class="xxxr-borders shading">28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xxxx-borders">14 (2)</td><td class="xxxx-borders">12 (2)</td><td class="xxxr-borders">26 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Serious adverse event — no. of events</td><td class="xxxx-borders shading">88</td><td class="xxxx-borders shading">104</td><td class="xxxr-borders shading">192</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">75 (12)</td><td class="xxxx-borders">75 (12)</td><td class="xxxr-borders">150 (12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At ≤4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">No. of serious adverse events</td><td class="xxxx-borders">35</td><td class="xxxx-borders">50</td><td class="xxxr-borders">85</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)</td><td class="xxxx-borders shading">33 (5)</td><td class="xxxx-borders shading">40 (7)</td><td class="xxxr-borders shading">73 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At &gt;4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of serious adverse events</td><td class="xxxx-borders shading">53</td><td class="xxxx-borders shading">54</td><td class="xxxr-borders shading">107</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of participants with ≥1 serious adverse event (%)</td><td class="xxxx-borders">47 (8)</td><td class="xxxx-borders">44 (7)</td><td class="xxxr-borders">91 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Death — no. (%)</td><td class="xxxx-borders shading">12 (2)</td><td class="xxxx-borders shading">19 (3)</td><td class="xxxr-borders shading">31 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At ≤4 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of deaths (%)</td><td class="xxxx-borders shading">5 (1)</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxr-borders shading">11 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of deaths considered to be related to tuberculosis (%)</td><td class="xxxx-borders">3 (&lt;1)</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxr-borders">5 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At &gt;4 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">No. of deaths (%)</td><td class="xxxx-borders">7 (1)</td><td class="xxxx-borders">13 (2)</td><td class="xxxr-borders">20 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">No. of deaths considered to be related to tuberculosis (%)</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">6 (1)</td><td class="xxxr-borders shading">8 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Adverse drug reaction — no. of participants (%)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">6 (1)</td><td class="xxxx-borders">11 (2)</td><td class="xxxr-borders">17 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Bacterial infection leading to hospitalization — no. of events</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">40</td><td class="xxxr-borders shading">80</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14" data-xml-align="left">No. of participants with ≥1 event (%)</td><td class="xbxx-borders">36 (6)</td><td class="xbxx-borders">30 (5)</td><td class="xbxr-borders">66 (5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events was used for grading the severity of adverse events. The primary safety outcome was an adverse event of grade 3 or higher that occurred during treatment and up to 30 days after the last dose of a trial drug. Serious adverse events were defined with the use of International Council for Harmonisation and Good Clinical Practice definitions as an adverse event that resulted in death, was life-threatening, led to hospitalization or prolonged existing hospitalization, resulted in persistent or clinically significant disability or incapacity, consisted of a congenital anomaly or birth defect, or was considered to be another important medical condition.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Participants may have had events both before and after the 4-month breakdown.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Adverse drug reactions during treatment and within 30 days after completion of treatment were assessed by the site investigator as being possibly, probably, or definitely related to the trial drugs. Further information on the adverse drug reactions, including event types and information on treatment discontinuations, is provided in Table S4.</div></div></div></figcaption></a><figcaption><div class="caption">Primary Safety Outcome, Serious Adverse Events, Deaths, Adverse Drug Reactions, and Suspected Bacterial Infections Leading to Hospitalization.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2104535_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2104535</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">WHO Global Tuberculosis Programme. Global tuberculosis report 2021. Geneva: World Health Organization, 2021 (<a href="https://www.who.int/publications/digital/global-tuberculosis-report-2021" target="_blank">https://www.who.int/publications/digital/global-tuberculosis-report-2021</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2021&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. <em>Lancet Glob Health</em> 2017;5(9):e898-e906.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2214-109X(17)30289-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28807188/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+global+burden+of+tuberculosis+mortality+in+children%3A+a+mathematical+modelling+study.&amp;publication_year=2017&amp;journal=Lancet+Glob+Health&amp;pages=e898-e906&amp;doi=10.1016%2FS2214-109X%2817%2930289-9&amp;pmid=28807188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. <em>Pediatr Infect Dis J</em> 2012;31:347-352.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/INF.0b013e318243e27b" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22315002/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302696600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+proposed+comprehensive+classification+of+tuberculosis+disease+severity+in+children.&amp;publication_year=2012&amp;journal=Pediatr+Infect+Dis+J&amp;pages=347-352&amp;doi=10.1097%2FINF.0b013e318243e27b&amp;pmid=22315002" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] nonsevere, smear-negative tuberculosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for severe respiratory tuberculosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. <em>Int J Tuberc Lung Dis</em> 2006;10:732-738.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16848333/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238718400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+spectrum+of+disease+in+children+treated+for+tuberculosis+in+a+highly+endemic+area.&amp;publication_year=2006&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=732-738&amp;pmid=16848333" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Loveday M, Sunkari B, Marais BJ, Master I, Brust JC. Dilemma of managing asymptomatic children referred with ‘culture-confirmed’ drug-resistant tuberculosis. <em>Arch Dis Child</em> 2016;101:608-613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/archdischild-2015-310186" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27044259/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378065400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dilemma+of+managing+asymptomatic+children+referred+with+%E2%80%98culture-confirmed%E2%80%99+drug-resistant+tuberculosis.&amp;publication_year=2016&amp;journal=Arch+Dis+Child&amp;pages=608-613&amp;doi=10.1136%2Farchdischild-2015-310186&amp;pmid=27044259" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. <em>J Infect Dis</em> 2012;206:1809-1815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jis608" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23033147/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311667400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Childhood+tuberculosis+and+malnutrition.&amp;publication_year=2012&amp;journal=J+Infect+Dis&amp;pages=1809-1815&amp;doi=10.1093%2Finfdis%2Fjis608&amp;pmid=23033147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Martinez L, Cords O, Horsburgh CR, Andrews JR; Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. <em>Lancet</em> 2020;395:973-984.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30166-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32199484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521744600028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+risk+of+tuberculosis+in+children+after+close+exposure%3A+a+systematic+review+and+individual-participant+meta-analysis.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=973-984&amp;doi=10.1016%2FS0140-6736%2820%2930166-5&amp;pmid=32199484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rapid+advice%3A+treatment+of+tuberculosis+in+children&amp;publication_year=2010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Graham SM, Grzemska M, Gie RP. The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. <em>Int J Tuberc Lung Dis</em> 2015;19:Suppl 1:3-8.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.15.0416" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26564534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365837300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+background+and+rationale+for+a+new+fixed-dose+combination+for+first-line+treatment+of+tuberculosis+in+children.&amp;publication_year=2015&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=3-8&amp;doi=10.5588%2Fijtld.15.0416&amp;pmid=26564534" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization, 2014.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidance+for+national+tuberculosis+programmes+on+the+management+of+tuberculosis+in+children&amp;publication_year=2014" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] revised doses and became available in 2015. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] using WHO-recommended pediatric doses. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] with the use of child-friendly formulations </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. <em>Trials</em> 2018;19:237-237.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-018-2608-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29673395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430599800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Shorter+treatment+for+minimal+tuberculosis+%28TB%29+in+children+%28SHINE%29%3A+a+study+protocol+for+a+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Trials&amp;pages=237-237&amp;doi=10.1186%2Fs13063-018-2608-5&amp;pmid=29673395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative Reference Case for economic evaluation: an aid to thought. <em>Value Health</em> 2016;19:921-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jval.2016.04.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27987641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396448300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+International+Decision+Support+Initiative+Reference+Case+for+economic+evaluation%3A+an+aid+to+thought.&amp;publication_year=2016&amp;journal=Value+Health&amp;pages=921-928&amp;doi=10.1016%2Fj.jval.2016.04.015&amp;pmid=27987641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. <em>Clin Infect Dis</em> 2015;61:Suppl 3:S179-S187.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ581" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26409281/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362952900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+case+definitions+for+classification+of+intrathoracic+tuberculosis+in+children%3A+an+update.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S179-S187&amp;doi=10.1093%2Fcid%2Fciv581&amp;pmid=26409281" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] clinical, radiologic, and laboratory data. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for diagnosis of intrathoracic tuberculosis </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Wills GH, Graham SM, Seddon JA, et al. A method for baseline adjudication of tuberculosis diagnosis in children in a therapeutic clinical trial: experience from SHINE. Proceedings and abstracts of the 51st Union World Conference on Lung Health, October 20–24, 2020. Paris: the International Union against Tuberculosis and Lung Disease, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+method+for+baseline+adjudication+of+tuberculosis+diagnosis+in+children+in+a+therapeutic+clinical+trial%3A+experience+from+SHINE&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. November 2014 (<a href="https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf">https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+%28DAIDS%29+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events.+Version+2.0&amp;publication_year=2014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Wademan DT, Busakwe L, Nicholson TJ, et al. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. <em>Int J Tuberc Lung Dis</em> 2019;23:1263-1268.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5588/ijtld.19.0115" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31931909/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502329600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Acceptability+of+a+first-line+anti-tuberculosis+formulation+for+children%3A+qualitative+data+from+the+SHINE+trial.&amp;publication_year=2019&amp;journal=Int+J+Tuberc+Lung+Dis&amp;pages=1263-1268&amp;doi=10.5588%2Fijtld.19.0115&amp;pmid=31931909" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Floyd K, Glaziou P, Sismanidis C, et al. Global tuberculosis report 2012. Geneva: World Health Organization, 2012.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2012&amp;publication_year=2012" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Kekitiinwa A, Cook A, Nathoo K, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. <em>Lancet</em> 2013;381:1391-1403.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)62198-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23473847/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317894800036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Routine+versus+clinically+driven+laboratory+monitoring+and+first-line+antiretroviral+therapy+strategies+in+African+children+with+HIV+%28ARROW%29%3A+a+5-year+open-label+randomised+factorial+trial.&amp;publication_year=2013&amp;journal=Lancet&amp;pages=1391-1403&amp;doi=10.1016%2FS0140-6736%2812%2962198-9&amp;pmid=23473847" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">WHO Global Tuberculosis Programme. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+tuberculosis+report+2019&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. <em>Ann Acad Med Singap</em> 2002;31:175-181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.47102/annals-acadmedsg.V31N2p175" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11957554/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000174808900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+chemotherapy+in+the+treatment+of+smear-negative+pulmonary+tuberculosis%3A+results+at+30+to+60+months.&amp;publication_year=2002&amp;journal=Ann+Acad+Med+Singap&amp;pages=175-181&amp;doi=10.47102%2Fannals-acadmedsg.V31N2p175&amp;pmid=11957554" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Hong Kong Chest Service, Madras Tuberculosis Research Centre, British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 5 years. <em>Am Rev Respir Dis</em> 1989;139:871-876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/ajrccm/139.4.871" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2648911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+3-month%2C+4-month%2C+and+6-month+regimens+of+chemotherapy+for+sputum-smear-negative+pulmonary+tuberculosis%3A+results+at+5+years.&amp;publication_year=1989&amp;journal=Am+Rev+Respir+Dis&amp;pages=871-876&amp;doi=10.1164%2Fajrccm%2F139.4.871&amp;pmid=2648911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Hong Kong Chest Service, Madras Tuberculosis Research Centre, British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 60 months. <em>Am Rev Respir Dis</em> 1984;130:23-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6377997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1984SZ87500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+2-month%2C+3-month%2C+and+12-month+regimens+of+chemotherapy+for+sputum-smear-negative+pulmonary+tuberculosis%3A+results+at+60+months.&amp;publication_year=1984&amp;journal=Am+Rev+Respir+Dis&amp;pages=23-28&amp;pmid=6377997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. <em>Nat Med</em> 2018;24:1708-1715.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0224-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30397355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449404200023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+patient-level+pooled+analysis+of+treatment-shortening+regimens+for+drug-susceptible+pulmonary+tuberculosis.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=1708-1715&amp;doi=10.1038%2Fs41591-018-0224-2&amp;pmid=30397355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. <em>N Engl J Med</em> 2021;384:1705-1718.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2104535&amp;key=10.1056%2FNEJMoa2033400&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33951360/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000647698500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Four-month+rifapentine+regimens+with+or+without+moxifloxacin+for+tuberculosis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1705-1718&amp;doi=10.1056%2FNEJMoa2033400&amp;pmid=33951360" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Global Alliance for TB Drug Development. New milestone for children with tuberculosis reached as one million treatments of child-friendly medicines are ordered. June 18, 2019 (<a href="https://www.tballiance.org/news/one-million-child-friendly-tuberculosis-medicines">https://www.tballiance.org/news/one-million-child-friendly-tuberculosis-medicines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+milestone+for+children+with+tuberculosis+reached+as+one+million+treatments+of+child-friendly+medicines+are+ordered&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis — rapid diagnostics for tuberculosis detection. July 7, 2021 (<a href="https://www.who.int/publications/i/item/9789240029415">https://www.who.int/publications/i/item/9789240029415</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=WHO+consolidated+guidelines+on+tuberculosis.+Module+3%3A+diagnosis+%E2%80%94+rapid+diagnostics+for+tuberculosis+detection&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. <em>Am J Respir Crit Care Med</em> 2011;184:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201103-0536OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21836139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296613900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multisite+assessment+of+the+quantitative+capabilities+of+the+Xpert+MTB%2FRIF+assay.&amp;publication_year=2011&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=1076-1084&amp;doi=10.1164%2Frccm.201103-0536OC&amp;pmid=21836139" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 22, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2204561" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Shorter Treatment for Tuberculosis in Children</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 09, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2200966" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Childhood Tuberculosis — Time for Shorter and Differentiated Treatment</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Pai and H.J. Zar</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 19, 2025</div><div class="nejm-widget_item"><div><span> Somersworth, New Hampshire</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893959/otolaryngologist-somersworth-nh/?query=fjwp&amp;rid=428606">Otolaryngologist - Somersworth, NH</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878299/orthopedist/?query=fjwp&amp;rid=980">Orthopedist</a></div></div><div class="nejm-widget_item"><div><span> Florida</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888363/child-or-adult-psychiatrist-ft-lauderdale-fl-outpatient-telehealth/?query=fjwf&amp;rid=377088">Child or Adult Psychiatrist - Ft. Lauderdale, FL - Outpatient / Telehealth</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888873/hematology-oncology-tx-metro-earn-in-the-top-1-percent-of-oncologists-in-the-us/?query=fjwf&amp;rid=5263">Hematology/Oncology | TX Metro | Earn in the Top 1% of Oncologists in the US</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Allergy &amp; Clinical Immunology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881547/physician-allergy/?query=fjwf&amp;rid=385607">Physician - Allergy</a></div></div><div class="nejm-widget_item"><div><span> Albuquerque, New Mexico</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/896037/primary-care-physician-optum-new-mexico/?query=fjwf&amp;rid=220874">Primary Care Physician - Optum New Mexico</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104535&amp;pubId=41395969&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="9523b0aab351010f-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="9523b0aab351010f-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="9523b0aab351010f-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$649155350$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$649155350$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$649155350$--></div></div><div class="mlt-body"><!--?lit$649155350$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$649155350$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$649155350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$649155350$-->Dec 19, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2314318?query=recirc_Semantic" target="_self">Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$649155350$-->A.C. Hesseling and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$649155350$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$649155350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$649155350$-->Dec 19, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2314325?query=recirc_Semantic" target="_self">Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam</a></div><div class="mlt-article-authors"><!--?lit$649155350$-->G.J. Fox and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$649155350$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$649155350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$649155350$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2308181?query=recirc_Semantic" target="_self">HIV-Associated Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$649155350$-->G. Meintjes and G. Maartens</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$649155350$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$649155350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$649155350$-->Oct 31, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2411285?query=recirc_Semantic" target="_self">HIV-Associated Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$649155350$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$649155350$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$649155350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$649155350$-->May 06, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2033400?query=recirc_Semantic" target="_self">Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis</a></div><div class="mlt-article-authors"><!--?lit$649155350$-->S.E. Dorman and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2104535?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2104535" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2104535.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2104535"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2110165" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>The Catfish King</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2111953" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f1.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/43eede6a-d10d-4747-a447-8ac89094fe5f/assets/images/large/nejmoa2104535_f1.jpg" height="3438" width="2622" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Randomization and Treatment of the Patients.</div><div class="notes"><div role="doc-footnote">All the eligible participants with tuberculosis (TB) initially received 8 weeks of standard therapy with isoniazid, rifampin, and pyrazinamide (fixed-dose combination formulation), with or without ethambutol according to local guidelines (intensive phase). This treatment was followed by standard therapy with isoniazid and rifampin (continuation phase) in a fixed-dose combination for either 8 weeks in the 4-month group (intervention) or 16 weeks in the 6-month group (control). MDR-TB denotes multidrug-resistant TB.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2104535_f2.jpg"><img src="/cms/10.1056/NEJMoa2104535/asset/ff43ac35-9290-4e67-85f4-534e13431073/assets/images/large/nejmoa2104535_f2.jpg" height="1115" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Unadjusted Analysis of the Primary Efficacy and Key Secondary Outcomes in the Trial Populations.</div><div class="notes"><div role="doc-footnote">The primary efficacy outcome was unfavorable status by 72 weeks, which was defined as a composite of treatment failure (treatment extension, change, or restart or tuberculosis recurrence), loss to follow-up during treatment, or death, with the exclusion of all the participants who had undergone randomization but did not complete 4 months of treatment (modified intention-to-treat population). The per-protocol population included all the participants in the modified intention-to-treat population except those who had not adhered to the trial regimen. The intention-to-treat population included all the participants who had undergone randomization. Differences have been carried to one decimal place because of the small values. The prespecified margin for noninferiority in the primary efficacy analysis was 6 percentage points (dashed line). The key secondary analysis was unfavorable status at 72 weeks as assessed among the 958 participants who had been independently adjudicated as having tuberculosis at baseline.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary Efficacy Analysis (Modified Intention-to-Treat Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Primary Safety Outcome, Serious Adverse Events, Deaths, Adverse Drug Reactions, and Suspected Bacterial Infections Leading to Hospitalization.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/10" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 10</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 10, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2116747" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.S.G. Sablerolles and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 10, 2022</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2117128" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.-Y. Lin and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 10, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2111953" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Leboulleux and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2104535%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104535&amp;pubId=41395969&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2104535%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2104535&amp;pubId=41395969&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id09622880590951856" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="9523b0aab351010f-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="9523b0aab351010f-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="9523b0aab351010f-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="9523b0aab351010f-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="9523b0aab351010f-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="9523b0aab351010f-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="9523b0aab351010f-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="9523b0aab351010f-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="9523b0aab351010f-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9523b0aa9edc010f',t:'MTc1MDM0MzA2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;9523b0aa9edc010f&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.6.2&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2104535?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=11-19"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-transactionid="yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" id="captureIFrame_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" target="captureIFrame_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="capture_screen"><input id="capture_signIn_js_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="js_version"><input id="capture_signIn_transactionId_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" type="hidden" class="capture_transactionId_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="capture_transactionId"><input id="capture_signIn_form_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="form"><input id="capture_signIn_flow_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="flow"><input id="capture_signIn_client_id_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="client_id"><input id="capture_signIn_redirect_uri_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="redirect_uri"><input id="capture_signIn_response_type_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="response_type"><input id="capture_signIn_flow_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="flow_version"><input id="capture_signIn_settings_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="settings_version"><input id="capture_signIn_locale_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="locale"><input id="capture_signIn_recaptcha_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_yl0vg4kbfg3ha27i5lkyopvdpedzr2p96m1wns5t" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>